Press coverage about Retrophin (NASDAQ:RTRX) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Retrophin earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.7893401269973 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several equities analysts have recently weighed in on RTRX shares. BidaskClub lowered shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Saturday, December 30th. ValuEngine lowered shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd. Finally, Zacks Investment Research lowered shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $44.00.
Retrophin (NASDAQ RTRX) opened at $23.03 on Wednesday. Retrophin has a 12-month low of $15.55 and a 12-month high of $26.44. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.83 and a current ratio of 3.88. The firm has a market cap of $905.23, a PE ratio of -17.45 and a beta of 1.26.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.